.4B, trading at NT$50.00 on the TWO. This SniperIQ fundamentals page covers Sagittarius Life Science's valuation, profitability (net margin -7.9%), revenue (NT46M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapNT
.4B
Net Margin-7.9%
Revenue (FY25)NT
46M

Full research coverage

Frequently Asked Questions

What is Sagittarius Life Science's market cap?

Sagittarius Life Science (3205) has a market capitalization of approximately NT

.4B, trading at NT$50.00 on the TWO. Market cap moves with the live share price.

What is Sagittarius Life Science's P/E ratio?

Sagittarius Life Science's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Sagittarius Life Science?

Sagittarius Life Science runs a net profit margin of -7.9%, a gross margin of 13.6%, and an operating margin of -10.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Sagittarius Life Science generate?

Sagittarius Life Science reported revenue of NT

46M for fiscal year 2025, with net income of -NT$50M and earnings per share (EPS) of -0.92. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Sagittarius Life Science pay a dividend?

Sagittarius Life Science does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Sagittarius Life Science financially healthy?

Sagittarius Life Science carries a debt-to-equity ratio of 0.02x and a current ratio of 11.77x, with a market beta of 0.30. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Sagittarius Life Science a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Sagittarius Life Science (3205) the key facts are: market cap NT

.4B, revenue NT46M, 52-week range 43.95-67. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Sagittarius Life Science's full fundamentals live

Get Sagittarius Life Science's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.